Accelr8 Announces Fiscal 2010 Positive Earnings
and Gain in Shareholders’ Equity
September 17, 2010 09:03 AM Eastern Daylight Time
DENVER--(EON: Enhanced Online News)--Accelr8 Technology Corporation (NYSE Amex: AXK) announced
its financial results for the fiscal year ended July 31, 2010. For the fiscal year, net sales revenues totaled $2,245,628;
net income from operations was $611,793 with total net income of $641,747. For the previous year, net sales were
$1,269,886 with a loss from operations of $(679,119) and a total net loss of $(714,197). Shareholders’ equity
totaled $4,909,778 for 2010, up from $3,894,494 at the end of the previous fiscal year.
Based upon these results, the company believes it complies with the applicable Amex listing requirement of $4 million
in shareholders’ equity. The company’s 10-K annual report to the SEC is available through the SEC’s Edgar
website, or the Edgar link through the company’s website at www.accelr8.com/investor_information.php.
Accelr8’s president, David Howson said, “we are very pleased not only with the profitable revenues but with the
primary source being a medical diagnostics company that has an exciting product line. Nanosphere’s acceptance of
OptiChem® coatings for use in new high-performance diagnostic products helps to build our visibility within the
medical community and the diagnostics industry.”
“Our outside academic collaborations for the BACcelTM rapid diagnostic platform also continue to make significant
progress. We now have three pre-clinical or clinical pilot studies running at Denver Health and the Barnes-Jewish
Hospital in St. Louis using clinical specimens from ICU patients,” Howson concluded.
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for
advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is
developing a rapid analytical platform for infectious pathogens, the BACcelTM system, based o